Per Lundkvist

Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Lundkvist, Per; Malmberg, Karin Blom; Lindström, Linda; Kindmark, Andreas

Part of JIMD Reports, 2026

• DOI for Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice
• Download full text (pdf) of Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Anvari, Ebrahim; Lundkvist, Per; Singh, Kailash; Espes, Daniel

Part of Acta Diabetologica, p. 1987-1996, 2025

• DOI for Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes
• Download full text (pdf) of Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Hill, Henrik; Lundkvist, Per; Tsatsaris, Georgios; Birnir, Bryndis et al.

Part of Scientific Reports, 2025

• DOI for Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial
• Download full text (pdf) of Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Lundkvist, Per; Grönberg, Annika; Carlsson, Per-Ola; Ludvigsson, Johnny et al.

Part of BMJ Open Diabetes Research & Care, 2024

• DOI for Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes
• Download full text (pdf) of Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Hill, Henrik; Elksnis, Andris; Lundkvist, Per; Ubhayasekera, Kumari et al.

Part of Biomedicines, 2022

• DOI for Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes
• Download full text (pdf) of Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Lundkvist, Per; Malmberg, Karin Blom; Lindström, Linda; Kindmark, Andreas

Part of JIMD Reports, 2026

• DOI for Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice
• Download full text (pdf) of Successful Management of Two Consecutive Pregnancies With Maternal-Fetal Phenylketonuria: Lessons From Clinical Practice

Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Anvari, Ebrahim; Lundkvist, Per; Singh, Kailash; Espes, Daniel

Part of Acta Diabetologica, p. 1987-1996, 2025

• DOI for Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes
• Download full text (pdf) of Proximity extension assay inflammatory profiling cannot distinguish the presence of residual C-peptide in patients with long-standing type 1 diabetes

Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Hill, Henrik; Lundkvist, Per; Tsatsaris, Georgios; Birnir, Bryndis et al.

Part of Scientific Reports, 2025

• DOI for Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial
• Download full text (pdf) of Long-term treatment with gamma-aminobutyric acid (GABA) fails to regain beta-cell function in longstanding type 1 diabetes: results from a randomized trial

Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Lundkvist, Per; Grönberg, Annika; Carlsson, Per-Ola; Ludvigsson, Johnny et al.

Part of BMJ Open Diabetes Research & Care, 2024

• DOI for Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes
• Download full text (pdf) of Predictive biomarkers of rapidly developing insulin deficiency in children with type 1 diabetes

Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Hill, Henrik; Elksnis, Andris; Lundkvist, Per; Ubhayasekera, Kumari et al.

Part of Biomedicines, 2022

• DOI for Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes
• Download full text (pdf) of Endogenous Levels of Gamma Amino-Butyric Acid Are Correlated to Glutamic-Acid Decarboxylase Antibody Levels in Type 1 Diabetes

Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Katsogiannos, Petros; Kamble, Prasad G.; Boersma, Greta J.; Karlsson, F. Anders et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 2601-2613, 2019

• DOI for Early Changes in Adipose Tissue Morphology, Gene Expression, and Metabolism After RYGB in Patients With Obesity and T2D

Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.

Lundkvist, Per; Pereira, Maria J.; Kamble, Prasad G.; Katsogiannos, Petros et al.

Part of Journal of Clinical Endocrinology and Metabolism, p. 193-201, 2019

• DOI for Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.

FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes

Sidibeh, Cherno O; Pereira, Maria J; Abalo, Xesus; Boersma, Gretha J. et al.

Part of Endocrine, p. 116-128, 2018

• DOI for FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes
• Download full text (pdf) of FKBP5 expression in human adipose tissue: potential role in glucose and lipid metabolism, adipogenesis and type 2 diabetes

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Eriksson, Jan W.; Lundkvist, Per; Jansson, Per-Anders; Johansson, Lars et al.

Part of Diabetologia, p. 1923-1934, 2018

• DOI for Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
• Download full text (pdf) of Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.

Kamble, Prasad G.; Pereira, Maria J; Gustafsson, Stefan; Lundkvist, Per et al.

Part of Adipocyte, p. 285-296, 2018

• DOI for Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.
• Download full text (pdf) of Role of peroxisome proliferator-activated receptor gamma Pro12Ala polymorphism in human adipose tissue: assessment of adipogenesis and adipocyte glucose and lipid turnover.

Direct effects of glucagon on human adipose tissue metabolism

Pereira, Maria J; Boersma, Greta J.; Kamble, Prasad G.; Lundkvist, Per et al.

Part of Diabetologia, 2018

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Pereira, Maria J; Lundkvist, Per; Kamble, Prasad G.; Lau, Joey et al.

Part of Diabetes Therapy, p. 1511-1532, 2018

• DOI for A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
• Download full text (pdf) of A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss

Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers

Kamble, Prasad G.; Gustafsson, Stefan; Pereira, Maria J; Lundkvist, Per et al.

Part of Upsala Journal of Medical Sciences, p. 234-242, 2017

• DOI for Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers
• Download full text (pdf) of Genotype-based recall to study metabolic effects of genetic variation: a pilot study of PPARG Pro12Ala carriers

Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Lundkvist, Per; Sjöström, C. David; Amini, Sam; Pereira, Maria J. et al.

Part of Diabetes, obesity and metabolism, p. 49-60, 2017

• DOI for Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
• Download full text (pdf) of Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

Lundkvist, Per; Pereira, Maria J; Katsogiannos, Petros; Sjöström, C. David et al.

Part of Diabetes, obesity and metabolism, p. 1276-1288, 2017

• DOI for Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
• Download full text (pdf) of Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

PPARG Pro12Ala variant in relation to adipose tissue metabolism and differentiation: a small genotype-based recall study

Kamble, Prasad G.; Pereira, Maria J; Gustafsson, Stefan; Lundkvist, Per et al.

Part of Diabetologia, 2017

Glucose homeostasis and whole-body insulin resistance improved 4 weeks after gastric bypass surgery in type 2 diabetes, whereas adipose tissue metabolism was unchanged

Katsogiannos, Petros; Boersma, Greta J.; Pereira, Maria J; Lundkvist, Per et al.

Part of Diabetologia, 2017

Glucagon levels during short-term SGLT2 inhibition are largely regulated by plasma glucose changes

Lundkvist, Per; Pereira, Maria J; Kamble, Prasad G.; Katsogiannos, Petros et al.

Part of Diabetologia, 2017

Effects of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, and free omega-3 carboxylic acids on liver steatosis and hepatocyte damage biomarkers in Type 2 diabetes patients with non-alcoholic fatty liver disease

Oscarsson, Jan; Lundkvist, Per; Jansson, Per-Anders E.; Johansson, Lars et al.

Part of Hepatology, 2016

One year of treatment with dapagliflozin QD plus exenatide QW in obese adults without diabetes: results of an open-label extension study

Eriksson, Jan W.; Lundkvist, Per; Sjöström, C.; Katsogiannos, Petros et al.

Part of Diabetologia, 2016

Metabolic effects of dapagliflozin QD and exenatide QW in obese adults without diabetes: a 24-week randomised placebo-controlled phase 2 study

Lundkvist, Per; Amini, Sam; Lau Börjesson, Joey; Pereira, Maria J. et al.

Part of Diabetologia, 2016

Metabolic and endocrine effects of SGLT2 inhibition

Lundkvist, Per

2019

• Download full text (pdf) of Metabolic and endocrine effects of SGLT2 inhibition